INTS Profile
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative cancer therapies aimed at treating solid tumors. The company’s primary product candidate, INT230-6, is currently in Phase 2 clinical trials targeting refractory solid tumors, including pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. INT230-6 is designed to improve the delivery and potency of anti-cancer agents directly into tumors, potentially offering a novel approach to cancer treatment with localized effects and reduced systemic toxicity.
Intensity Therapeutics has established significant collaborations to advance its research and development efforts. The company has a partnership with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda, a leading immunotherapy drug, in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is focused on testing the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers. These partnerships are instrumental in exploring the potential synergistic effects of combining INT230-6 with established immunotherapies.
In addition to its collaborations with major pharmaceutical companies, Intensity Therapeutics is engaged in academic partnerships to further its research. The company is working with the Ottawa Hospital Research Institute and the Ontario Institute for Cancer Research to study INT230-6 in a randomized controlled neoadjuvant Phase 2 study in women with early-stage breast cancer. These academic collaborations provide valuable clinical insights and contribute to the robust evaluation of INT230-6's therapeutic potential across different cancer types and stages.
Founded in 2012 and headquartered in Westport, Connecticut, Intensity Therapeutics is committed to transforming the cancer treatment landscape through its pioneering approach to drug delivery. By focusing on direct intratumoral injection and leveraging the body’s immune response, the company aims to develop more effective and less toxic cancer treatments. Intensity Therapeutics' innovative strategies and strong collaborative efforts position it at the forefront of cancer therapy development, striving to improve outcomes for patients with challenging and refractory cancers.
|
